A Beta-only IL-2 ImmunoTherapY Study

Key Inclusion Criteria:

1. Aged at least 18 years (inclusive at the time of informed consent).

2. Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 to 1.

3. Must be able and willing to provide written informed consent prior to start of anystudy procedures and assessments and must be willing to comply with all studyprocedures.

4. Histologically or cytologically confirmed locally advanced or metastatic solid tumor (see tumor types listed under conditions)

5. Demonstrated adequate organ function

6. Measurable disease as per Response Evaluation Criteria in Solid Tumors, (RECISTv1.1) and documented by CT and/or MRI.

7. Life expectancy of ≥ 12 weeks.

8. Women of childbearing potential (WOCBP) must have a negative pregnancy test atscreening and within 72 hours before the first dose of study drug(s). Women must notbe breastfeeding.

9. Agree to use highly effective contraception methods. WOCBP must agree to use highlyeffective birth control.

Key Exclusion Criteria:

1. Last administration of prior antitumor therapy:

• Prior systemic anti-cancer therapy including investigational agents within 4weeks (could consider shorter interval for kinase inhibitors or other shorthalf-life drugs) prior to start of treatment.

• Prior radiotherapy within 2 weeks prior to start of treatment or has had ahistory of radiation pneumonitis. A 1-week washout is required for palliativeradiation (<2 weeks of radiotherapy) to non-CNS disease.

• Radiation therapy to the lung that is > 30Gy within 6 months prior to start oftreatment.

• Currently participating in or has participated in a study of an investigationalagent or has used an investigational device within 4 weeks prior to start oftreatment. Concomitant participation in an observational study must bediscussed on a case-by-case basis with the MM for approval.

2. Has known active CNS metastases and/or carcinomatous meningitis. Patients withpreviously treated brain metastases may participate provided they are radiologicallystable, i.e., without evidence of progression for at least 4 weeks by repeat imaging (note that the repeat imaging should be performed during study screening),clinically stable and without requirement of steroid treatment for at least 14 daysprior to start of treatment, subject to discussion with MM.

3. Active malignancy (other than the disease under treatment in the study) within theprevious 3 years except for curable cancers.

4. Condition requiring long-term systemic treatment with either corticosteroids > 10 mgdaily prednisone equivalent or any other form of immunosuppressive therapy within 7days prior to start of treatment.

5. Clinically significant active, known or suspected autoimmune disease, or diseasesthat can be exacerbated with immunotherapy.

6. Severe pulmonary, cardiac or other systemic disease.

7. Known hepatitis B or C virus infection.

8. Females who are pregnant or lactating or planning to become pregnant during thestudy.

9. Has had an allogeneic tissue/solid organ transplant.

10. Active infection requiring systemic therapy.

11. Any medical, emotional or psychiatric condition that interfere with the patient'sability to adhere to the protocol

12. Any other underlying medical conditions that, in the Investigator's opinion, willmake the administration of study drug(s) unsafe or obscure the interpretation oftoxicity determination or adverse events.

13. Known severe hypersensitivity to any component of study drug(s).

14. Inability to comply with study and follow up procedures as judged by theInvestigator.